Nrx Pharmaceuticals, Inc. (NRXP) has disclosed a new risk, in the Accounting & Financial Operations category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nrx Pharmaceuticals, Inc. faces a broad spectrum of operational, clinical, regulatory, financial, and governance risks that collectively render its securities highly speculative. Its limited operating history, dependence on external capital and third-party manufacturers, and reliance on successful late-stage clinical trials, particularly for NRX-101, underscore the potential for material volatility in results and valuation.
In addition, heightened regulatory exposure, uncertain intellectual property protections, and constraints related to controlled substances compound execution risk across development and commercialization. Investors are therefore urged to review the detailed “Risk Factors” in the company’s Form 10-K, as the summarized items do not encompass all of the material risks and uncertainties that may adversely affect the business and its stock.
The average NRXP stock price target is $39.33, implying 1,746.48% upside potential.
To learn more about Nrx Pharmaceuticals, Inc.’s risk factors, click here.